Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
暂无分享,去创建一个
M. Carducci | L. Siu | A. Kalita | W. Messersmith | R. Martell | I. Durán | R. Pili | E. Chen | Zuomei Li | J. Besterman | M. Maclean | G. Reid | E. Laille | S. Brown | R. Sullivan | S. King | Serina King
[1] K. Glaser. HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.
[2] T. Kuzel,et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Abass Alavi,et al. Functional Imaging of Cancer with Emphasis on Molecular Techniques , 2007, CA: a cancer journal for clinicians.
[4] A. Kalita,et al. A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS) , 2007 .
[5] L. Natarajan,et al. The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review , 2007, Brain, Behavior, and Immunity.
[6] J. Mehnert,et al. Histone Deacetylase Inhibitors: Biology and Mechanism of Action , 2007, Cancer journal.
[7] A. El-Osta,et al. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? , 2007, Leukemia.
[8] K. Bhalla,et al. A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.
[9] Mostafa Atri,et al. New technologies and directed agents for applications of cancer imaging. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Dokmanovic,et al. Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.
[11] E. Sausville,et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Robert Brown,et al. A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours , 2005 .
[14] Ping Zhu,et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.
[15] K. Glaser,et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.
[16] J. Marshall,et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. , 2002, Journal of experimental therapeutics & oncology.
[17] D. O’Carroll,et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.
[18] S. Bates,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[20] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[21] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[22] T. Kouzarides. Histone acetylases and deacetylases in cell proliferation. , 1999, Current opinion in genetics & development.
[23] S. Schreiber,et al. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. , 1997, Current opinion in chemical biology.